[go: up one dir, main page]

WO2018004014A1 - Protéine recombinée ayant une activité transglutaminase - Google Patents

Protéine recombinée ayant une activité transglutaminase Download PDF

Info

Publication number
WO2018004014A1
WO2018004014A1 PCT/JP2017/024881 JP2017024881W WO2018004014A1 WO 2018004014 A1 WO2018004014 A1 WO 2018004014A1 JP 2017024881 W JP2017024881 W JP 2017024881W WO 2018004014 A1 WO2018004014 A1 WO 2018004014A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
protein
mtg
activity
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/024881
Other languages
English (en)
Japanese (ja)
Inventor
典穂 神谷
浩之輔 林
孝介 南畑
松崎　隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
Original Assignee
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC filed Critical Kyushu University NUC
Priority to JP2018525324A priority Critical patent/JPWO2018004014A1/ja
Publication of WO2018004014A1 publication Critical patent/WO2018004014A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Definitions

  • the present invention relates to a recombinant protein having transglutaminase activity. Specifically, the present invention relates to the above recombinant protein in which the amino acid of the propeptide portion of the microorganism-derived transglutaminase is mutated.
  • Transglutaminase is an acyl group transfer between a specific glutamine (Q) side chain ⁇ -carboxyamide group and a primary amine including an amine group of lysine (K) side chain, or water.
  • a post-translational modification enzyme that catalyzes the reaction and forms an isopeptide bond.
  • MMG microtransglutaminase derived from Streptomyces mobaraensis does not require a cofactor for the expression of catalytic activity, and is easily expressed in large quantities by a microbial host, and has a cross-linking activity (that is, the above isoforms).
  • Non-Patent Documents 1 and 2). the application range of MTG is expanding, and further application can be expected by improving its function.
  • E. coli expression system which is a general-purpose host for gene recombination, it is difficult to express the mature form of MTG itself, and it has been reported that it is insolubilized (Patent Document 1).
  • MTG has a partial structure called a propeptide and a structure called a precursor fused to the N-terminal side of mature MTG.
  • This propeptide is an intramolecular chaperone that leads to the correct folding of MTG. It can be said that it is indispensable to acquire. Therefore, in a state where a propeptide is added, expression in E. coli is possible (see Non-Patent Document 3).
  • the MTG variant expressed with the propeptide added does not show activity due to the presence of the propeptide covering the active site. Therefore, it has been difficult to prepare an active recombinant MTG using E. coli as a host.
  • Patent Document 2 In previous studies, in order to solve the above-mentioned problems, the MTG precursor and the protease are co-expressed in the E. coli cytoplasm, thereby succeeding in obtaining active MTG simultaneously with the expression. In addition, a search for a more highly active MTG in which a propeptide is easily removed after protease treatment by screening a plurality of mutants by introducing a mutation into an amino acid in the propeptide and studying an expression process has been carried out ( Non-patent document 2).
  • a linker peptide is a peptide that does not have a fixed secondary structure and has some flexibility to satisfy biological conditions.
  • polyglycine, GS, and PT PTPPTTPT
  • the specific activity increased in all mutants compared to the wild type.
  • those with GS and PT linker inserted showed high specific activity.
  • the catalytic efficiency of the enzyme increased because the value of k cat / K m increased in the mutant with the linker inserted. This is presumably because the linker peptide is located in the vicinity of the active site, and the catalytic efficiency is increased by the interaction between the linker peptide and the catalytic region.
  • Non-Patent Document 4 the activity of MTG has been successfully improved by adding a specific sequence to the propeptide.
  • this problem can be cleared by co-expressing a recombinant MTG and a protease in an E. coli host (see Non-Patent Document 2).
  • MTG undergoes partial hydrolysis, leading to inactivation.
  • the reaction efficiency of MTG is lowered, which may affect the subsequent reaction. In any case, a protease treatment and a subsequent purification process are necessary, and an increase in costs associated with this may be considered.
  • the problem to be solved by the present invention is an active MTG (MTG variant having transglutaminase activity) that does not require protease treatment in a protein expression system using a general-purpose host such as Escherichia coli, a method for producing the same, etc. Is to provide.
  • the present inventor has intensively studied to solve the above problems. As a result, a mutant that expresses transglutaminase activity (crosslinking activity) in the state of an MTG precursor, that is, a state having a propeptide was searched.
  • the above activity is spontaneously expressed even in a state having a propeptide by modifying the propeptide possessed by the MTG precursor by genetic engineering and regulating the interaction between the active site and the propeptide.
  • the present invention was completed by finding an MTG variant. That is, the present invention is as follows. (1) A protein obtained by mutating at least an amino acid in the amino acid sequence of a propeptide portion in a wild-type microorganism-derived transglutaminase, wherein the protein has transglutaminase activity. (2) The protein according to (1) above, which has the activity in a state having the propeptide portion after the mutation. (3) The protein according to (1) or (2) above, wherein the mutation is substitution with another amino acid.
  • amino acid in the amino acid sequence of the propeptide portion to be mutated contains lysine and / or at least one tyrosine.
  • the other amino acid obtained by mutating the at least one tyrosine is at least one selected from the group consisting of alanine, glutamine and histidine.
  • amino acids obtained by mutating the lysine are arginine, aspartic acid, glutamic acid, alanine, cysteine, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, asparagine, proline, glutamine, serine, threonine, valine, tryptophan.
  • protein according to (4) which is at least one selected from the group consisting of tyrosine.
  • a protein comprising an amino acid sequence in which one or several amino acids excluding the amino acid at the substitution site are deleted, substituted, or added, and has transglutaminase activity.
  • the protein according to (7), wherein the other amino acid obtained by mutating the 12th and / or 16th amino acid is at least one selected from the group consisting of alanine, glutamine and histidine.
  • amino acids obtained by mutating the tenth amino acid are arginine, aspartic acid, glutamic acid, alanine, cysteine, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, asparagine, proline, glutamine, serine, threonine ,
  • the protein according to (7) which is at least one selected from the group consisting of valine, tryptophan and tyrosine.
  • (10) The following protein (a) or (b): (A) an amino acid sequence in which at least one amino acid selected from the group consisting of the 10th, 12th and 16th amino acids is substituted with another amino acid in the amino acid sequence shown in SEQ ID NO: 2 (b) (a) A protein having a transglutaminase activity, comprising an amino acid sequence in which one or several amino acids excluding the amino acid at the substitution site in the amino acid sequence are deleted, substituted or added, and having the transglutaminase activity (11)
  • the protein according to (10) above, wherein the other amino acid obtained by mutating the second amino acid is at least one selected from the group consisting of alanine, glutamine and histidine.
  • amino acids obtained by mutating the tenth amino acid are arginine, aspartic acid, glutamic acid, alanine, cysteine, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, asparagine, proline, glutamine, serine, threonine.
  • the protein according to (10) above which is at least one selected from the group consisting of valine, tryptophan and tyrosine.
  • the transglutaminase activity according to any one of (1) to (12), wherein the transglutaminase activity has an activity level substantially equivalent to the transglutaminase activity of a wild-type microorganism-derived transglutaminase.
  • a gene comprising the following DNA (a) or (b): (A) In the base sequence shown in SEQ ID NO: 1, the 28th to 30th bases have been replaced with bases indicating codons of amino acids other than lysine, and / or the 34th to 36th and / or Alternatively, DNA consisting of a base sequence in which the 46th to 48th bases are replaced with bases indicating codons of amino acids other than tyrosine.
  • Amino acids other than lysine are composed of arginine, aspartic acid, glutamic acid, alanine, cysteine, phenylalanine, glycine, histidine, isoleucine, leucine, methionine, asparagine, proline, glutamine, serine, threonine, valine, tryptophan and tyrosine.
  • the gene according to (15) above which is at least one selected from the group.
  • a recombinant vector comprising the gene according to any one of (14) to (17) above.
  • a transformant comprising the recombinant vector according to (18) above.
  • MTG precursor means MTG having a propeptide portion
  • MTG mutant means MTG obtained by mutating (substituting) an amino acid in the MTG precursor.
  • the protein of the present invention is a mutant protein of transglutaminase (MTG) derived from a microorganism (Streptomyces mobaaraensis).
  • MTG transglutaminase
  • the protein of the present invention is a protein obtained by mutating at least an amino acid in the amino acid sequence of the propeptide portion in wild-type MTG, and having transglutaminase activity. It has the activity in a state having a mutated propeptide portion (a state in which the mutated propeptide portion is present in a protein molecule).
  • propeptide portion a partial structure called a propeptide (propeptide portion) is present in the form of being fused to the N-terminal side of mature MTG.
  • the so-called fusion protein of mature MTG and the propeptide portion is referred to as an MTG precursor.
  • the propeptide portion serves as an inhibitor and has a role for expressing transglutaminase activity (crosslinking activity) at an appropriate location.
  • This cross-linking activity is a post-translational modification between a primary amine including a specific glutamine (Q) side chain ⁇ -carboxyamide group and a lysine (K) side chain amine group, or water.
  • the propeptide portion in MTG is an intramolecular chaperone that leads to correct folding of the protein, and is indispensable for obtaining active MTG, that is, MTG having the above-mentioned crosslinking activity.
  • actinomycetes which is the original host of MTG
  • the MTG precursor is first expressed, and then the propeptide portion is removed by a unique protease secreted by the host to become mature MTG.
  • E. coli expression system which is a general-purpose host for gene recombination, the expression of mature MTG itself is difficult (is insolubilized).
  • the protein of the present invention is a protein in which at least an amino acid in the amino acid sequence of the propeptide portion is mutated in a wild-type microorganism-derived transglutaminase and has transglutaminase activity.
  • those having the activity in the state having the propeptide portion after the mutation, and the mutation being a substitution with another amino acid.
  • the amino acid to be substituted preferably contains at least one tyrosine.
  • the other amino acid after substitution is preferably at least one selected from the group consisting of alanine, glutamine and histidine.
  • the amino acid to be substituted preferably contains lysine, and in this case, other amino acids after substitution include arginine, aspartic acid, glutamic acid, glycine, asparagine, alanine, cysteine, glutamine, serine, threonine (threonine ), Preferably at least one selected from the group consisting of tryptophan, phenylalanine, isoleucine, leucine, methionine, proline, valine, tyrosine and histidine, more preferably at least one selected from the group consisting of aspartic acid and glutamic acid It is.
  • the protein of the present invention for example, in the amino acid sequence of wild-type microorganism-derived transglutaminase, at least one amino acid selected from the group consisting of the 10th, 12th and 16th amino acids is substituted with another amino acid. It comprises an amino acid sequence or an amino acid sequence in which one or several amino acids excluding the amino acid at the substitution site in the substituted amino acid sequence are deleted, substituted or added, and has transglutaminase activity Protein is preferred.
  • the amino acid sequence of wild-type microorganism-derived transglutaminase is an amino acid sequence excluding the signal peptide part of wild-type microorganism-derived transglutaminase, and a methionine residue (M) is added to the N-terminus thereof. It means the amino acid sequence.
  • the “amino acid sequence in which one or several amino acids are deleted, substituted or added” is, for example, about 1 to 10, preferably 1 to several, 1 to 5, 1 to 4 It is preferable that the amino acid sequence has one, three, one, two, or one amino acid deleted, substituted or added.
  • the introduction of mutation such as deletion, substitution or addition may be carried out by a mutation introduction kit utilizing site-directed mutagenesis, for example, GeneTailor. TM Site-Directed Mutagenesis System (Invitrogen), and TaKaRa Site-Directed Mutagenesis System (Prime STAR (registered trademark) Mutagenesis Basal kit, Muta (registered trademark)-Super Ex. Can do. Whether or not the above deletion, substitution or addition mutation has been introduced can be confirmed using various amino acid sequencing methods and structural analysis methods such as X-ray and NMR.
  • the other amino acid is not particularly limited as far as the 12th and / or 16th amino acid residue is other than tyrosine, but for example, at least one selected from the group consisting of alanine, glutamine and histidine. Species can preferably be mentioned.
  • the tenth amino acid residue is not particularly limited as long as it is other than lysine.
  • the 10th amino acid for example, the production of a self-crosslinked product of MTG itself can be suppressed while maintaining the crosslinking activity of MTG.
  • the protein of the present invention is also preferably the following protein (a) or (b).
  • (B) a transglutaminase activity comprising an amino acid sequence in which one or several amino acids except the amino acid at the substitution site are deleted, substituted or added in the amino acid sequence of the above (a) (the amino acid sequence after the substitution) Protein with
  • the amino acid sequence shown in SEQ ID NO: 2 is an amino acid sequence obtained by adding a methionine residue (M) to the N-terminus of the amino acid sequence excluding the signal peptide portion of the wild-type microorganism-derived transglutaminase, It is an amino acid sequence consisting of a total of 376 amino acids.
  • the protein of (b) is one or several (for example, about 1 to 10, preferably 1 to several, except for the amino acid at the substitution site in the amino acid sequence contained in the protein of (a). Any protein may be used as long as it has a transglutaminase activity and has an amino acid sequence in which 5 to 1, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid is deleted, substituted or added. There is no limitation.
  • the method for introducing a mutation such as deletion, substitution or addition and the confirmation of whether or not a mutation has been introduced are the same as described above.
  • the protein of the following (c) other than the protein of said (b) is mentioned, for example.
  • the protein of (c) those having the above identity of 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more are more preferable.
  • the proteins (b) and (c) can also be prepared by genetic engineering using a gene encoding the amino acid sequence of the protein.
  • the transglutaminase activity can be evaluated and measured by, for example, a method by fluorescence resonance energy transfer (FRET) described in Examples described later.
  • FRET fluorescence resonance energy transfer
  • the proteins (a) to (c) in the present invention may be in the state where the propeptide portion is fused (bound) to the N-terminal side of the mature MTG as in the case of the wild-type MTG.
  • those having a linker sequence between the propeptide portion and the N-terminal side of mature MTG are also preferred.
  • the linker sequence is not limited, but may be an amino acid sequence of about 1 to 30 residues, and specific examples thereof include GGGSLVPRGSGGS (thrombin linker sequence; SEQ ID NO: 10).
  • GGGSLVPRGSGGS thrombin linker sequence
  • SEQ ID NO: 10 wild-type MTG
  • the amino acid sequence from the N-terminal side to the 46th amino acid (proline) is the propeptide portion, and the 47th amino acid (aspartic acid) side to the C-terminal side.
  • the proteins (a) to (c) referred to in the present invention may be peptides derived from natural products, or may be obtained by artificial chemical synthesis, and are not limited.
  • a protein derived from a natural product may be obtained directly from a natural product by known recovery and purification methods, or a gene encoding the protein is incorporated into various expression vectors by a known gene recombination technique. After being introduced into cells and expressed, they may be obtained by known recovery and purification methods.
  • a commercially available kit such as a reagent kit PROTEIOS TM (Toyobo), TNT TM System (Promega), PG-Mate of synthesizer TM
  • the protein may be produced by a cell-free protein synthesis system using Toyobo and RTS (Roche Diagnostics), and may be obtained by a known recovery method and purification method, and is not limited.
  • Chemically synthesized proteins can be obtained using known protein synthesis methods.
  • the synthesis method include an azide method, an acid chloride method, an acid anhydride method, a mixed acid anhydride method, a DCC method, an active ester method, a carboimidazole method, and a redox method.
  • the solid phase synthesis method and the liquid phase synthesis method can be applied to the synthesis.
  • a commercially available protein synthesizer may be used.
  • the protein can be purified by combining known purification methods such as chromatography.
  • a derivative of the protein can be included together with or instead of the proteins (a) to (c). The derivative is meant to include all those that can be prepared from the protein.
  • the protein (a) to (c) and / or a derivative of the protein can be included together with or in place of the protein and / or a salt of the derivative.
  • the salt is preferably a physiologically acceptable acid addition salt or basic salt.
  • Acid addition salts include, for example, salts with inorganic acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, or acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, apple
  • inorganic acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, or acetic acid
  • propionic acid fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid
  • organic acids such as acid, oxalic acid, benzoic acid, methanesulfonic acid, and benzenesulfonic acid.
  • Examples of basic salts include salts with inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide and magnesium hydroxide, and salts with organic bases such as caffeine, piperidine, trimethylamine and pyridine.
  • the salt can be prepared using a suitable acid such as hydrochloric acid or a suitable base such as sodium hydroxide.
  • a suitable acid such as hydrochloric acid or a suitable base such as sodium hydroxide.
  • it can be prepared by treatment using standard protocols in water or in a liquid containing an inert water-miscible organic solvent such as methanol, ethanol or dioxane.
  • Recombinant gene Although it does not limit as a gene which codes the protein of this invention mentioned above, The gene containing DNA of the following (a) or (b) is mentioned preferably.
  • the following DNAs (a) and (b) are preferably structural genes of the protein of the present invention, but the gene containing these DNAs may be composed only of these DNAs.
  • these DNAs may be included in part, and may also include known base sequences (transcription promoter, SD sequence, Kozak sequence, terminator, etc.) necessary for gene expression, and is not limited.
  • SEQ ID NO: 1 the 28th to 30th bases have been replaced with bases indicating codons of amino acids other than lysine, and / or the 34th to 36th and / or Alternatively, DNA consisting of a base sequence in which the 46th to 48th bases are replaced with bases indicating codons of amino acids other than tyrosine.
  • the term “codon” means not only a three-base chain (triplet) on the RNA sequence after transcription but also a three-base chain on the DNA sequence. Therefore, the notation of the codon on the DNA sequence is performed using thymine (T) instead of uracil (U).
  • the base sequence shown in SEQ ID NO: 1 is a base sequence consisting of 1131 bases encoding wild-type microorganism-derived transglutaminase.
  • the nucleotide sequence of SEQ ID NO: 1 is an amino acid sequence obtained by adding a methionine residue (M) to the N-terminus of the amino acid sequence excluding the signal peptide portion of wild-type microorganism-derived transglutaminase.
  • M methionine residue
  • the DNA of (a) above is preferably a DNA in which the base showing the codons of amino acids other than tyrosine is a base showing at least one codon selected from the group consisting of alanine, glutamine and histidine.
  • the bases indicating the codons of amino acids other than lysine are arginine, aspartic acid, glutamic acid, glycine, asparagine, alanine, cysteine, glutamine, serine, threonine (threonine), tryptophan, phenylalanine.
  • a base showing at least one codon selected from the group consisting of isoleucine, leucine, methionine, proline, valine, tyrosine and histidine, more preferably at least one selected from the group consisting of aspartic acid and glutamic acid Preferred is DNA in the case of a base representing a codon. .
  • Such mutation-substituted DNAs are described in, for example, Molecular Cloning, A Laboratory Manual 4th ed. , Cold Spring Harbor Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997) and the like. Specifically, it can be prepared using a mutation introduction kit using site-directed mutagenesis by a known method such as the Kunkel method or Gapped duplex method, and examples of the kit include QuickChange.
  • TM Site-Directed Mutagenesis Kit (Stratagene), GeneTailor TM Preferred examples include Site-Directed Mutagenesis System (manufactured by Invitrogen), TaKaRa Site-Directed Mutagenesis System (Mutan-K, Mutan-Super Express Km, etc .: manufactured by Takara Bio Inc.) and the like.
  • Site-Directed Mutagenesis System manufactured by Invitrogen
  • TaKaRa Site-Directed Mutagenesis System Matan-K, Mutan-Super Express Km, etc .: manufactured by Takara Bio Inc.
  • PCR primers designed so that a missense mutation is introduced so as to be a base indicating a codon of a desired amino acid using a DNA containing a base sequence encoding wild-type MTG as a template under appropriate conditions It can also be prepared by performing PCR.
  • the DNA polymerase used for PCR is not limited, but is preferably a highly accurate DNA polymerase.
  • Pwo DNA Polymerase Roche Diagnostics
  • Pfu DNA polymerase Promega
  • Platinum Pfx DNA polymerase Invitrogen
  • KOD DNA polymerase Toyobo
  • KOD-plus-polymerase Toyobo
  • the PCR reaction conditions may be appropriately set depending on the optimum temperature of the DNA polymerase to be used, the length and type of the DNA to be synthesized, etc. For example, in the case of cycle conditions, “90-98 ° C. for 5-30 seconds (thermal denaturation, Dissociation) ⁇ 50 to 65 ° C.
  • the DNA of the above (b) uses the DNA of the above (a) or a DNA comprising a complementary base sequence, or a fragment thereof, as a probe, such as colony hybridization, plaque hybridization, Southern blot, etc. It can be obtained from a cDNA library or a genomic library by performing a known hybridization method. A library prepared by a known method may be used, or a commercially available cDNA library or genomic library may be used, and is not limited. For details of the hybridization procedure, see Molecular Cloning, A Laboratory Manual 3rd ed.
  • “Stringent conditions” in carrying out the hybridization method are conditions at the time of washing after hybridization, wherein the buffer salt concentration is 15 to 330 mM, the temperature is 25 to 65 ° C., preferably the salt concentration is 15 to It means a condition of 150 mM and a temperature of 45 to 55 ° C. Specifically, for example, conditions such as 50 mM at 80 mM can be exemplified. Furthermore, in addition to the conditions such as salt concentration and temperature, various conditions such as probe concentration, probe length, reaction time, etc. are taken into account, and the conditions for obtaining the DNA of (b) above are appropriately set. Can do.
  • the hybridizing DNA is preferably a base sequence having at least 40% homology (identity) to the DNA base sequence of (a) above, more preferably 60%, 80% or more, Examples include base sequences having 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identity.
  • the base corresponding to the base at the substitution site is the same as the base at the substitution site.
  • the “substitution site” referred to here is a site of base substitution made in the base sequence contained in the DNA of (a) above. Specifically, a base (triplet) indicating a modified codon generated by the base substitution.
  • the DNA of (b) is, for example, a base that is not completely identical in terms of base sequence, but is completely identical in translated amino acid sequence compared to the DNA of (a) above.
  • a DNA consisting of a sequence that is, a DNA obtained by subjecting the DNA of (a) to a silent mutation
  • codons corresponding to individual amino acids after translation are not particularly limited.
  • codons generally used in mammals such as humans after transcription DNA that shows a codon that is commonly used in microorganisms such as Escherichia coli and yeast, plants, etc. (preferably a codon that is frequently used).
  • the gene encoding the protein of the present invention may include a DNA encoding the amino acid sequence of the linker sequence when the protein includes the linker sequence described above. 3.
  • Recombinant vector and transformant In order to express the protein of the present invention, it is necessary to first construct a recombinant vector by incorporating the above-described gene of the present invention into an expression vector.
  • a transcription promoter an SD sequence (when the host is a prokaryotic cell), and a Kozak sequence (when the host is a eukaryotic cell) are ligated upstream in advance as necessary.
  • a terminator may be linked downstream, and an enhancer, splicing signal, poly A addition signal, selection marker, etc. may be linked.
  • Each element necessary for gene expression such as the above transcription promoter may be included in the gene from the beginning, or may be used when originally included in the expression vector.
  • a use aspect is not specifically limited.
  • As a method for incorporating the gene into the expression vector various methods using known gene recombination techniques such as a method using a restriction enzyme and a method using topoisomerase can be employed.
  • the expression vector is not limited as long as it can hold the gene encoding the protein of the present invention, such as plasmid DNA, bacteriophage DNA, retrotransposon DNA, retroviral vector, artificial chromosome DNA, and the like.
  • a vector suitable for the host cell to be used can be appropriately selected and used.
  • the constructed recombinant vector is introduced into a host to obtain a transformant, which is cultured, whereby the protein of the present invention can be expressed.
  • the “transformant” as used in the present invention means a gene into which a foreign gene has been introduced into the host, for example, a gene into which a foreign gene has been introduced by introducing plasmid DNA or the like into the host (transformation), Also included are those in which a foreign gene has been introduced by infecting a host with various viruses and phages (transduction).
  • the host is not limited as long as it can express the protein of the present invention after the introduction of the above recombinant vector, and can be selected as appropriate. For example, various animal cells such as humans and mice can be selected. And known hosts such as various plant cells, bacteria, yeast, and plant cells.
  • animal cells for example, human fibroblasts, CHO cells, monkey cells COS-7, Vero, mouse L cells, rat GH3, human FL cells and the like are used. Insect cells such as Sf9 cells and Sf21 cells can also be used.
  • bacteria for example, Escherichia coli, Bacillus subtilis and the like are used.
  • yeast is used as a host, for example, Saccharomyces cerevisiae and Schizosaccharomyces pombe are used.
  • plant cells for example, tobacco BY-2 cells are used.
  • the method for obtaining the transformant is not limited and can be appropriately selected in consideration of the combination of the host and expression vector.
  • electroporation, lipofection, heat shock, PEG, Preferred examples include calcium phosphate method, DEAE dextran method, and methods of infecting various viruses such as DNA virus and RNA virus.
  • the codon type of the gene contained in the recombinant vector may be the same as or different from the codon type of the host actually used, and is not limited. 4).
  • Protein production Specifically, the production of the protein of the present invention can be carried out by a method including a step of culturing the above-described transformant and a step of collecting a protein having transglutaminase activity from the obtained culture.
  • cultured product means any of culture supernatant, cultured cells, cultured cells, or disrupted cells or cells.
  • the transformant can be cultured according to a usual method used for host culture.
  • the protein of interest is accumulated in the culture.
  • the collecting step may include a protein purification step.
  • the medium used for the culture any known natural medium and any known medium can be used as long as it contains a carbon source, a nitrogen source, inorganic salts, and the like that can be assimilated by the host, and can efficiently culture the transformant. Any synthetic medium may be used.
  • the cells may be cultured under selective pressure in order to prevent the recombinant vector contained in the transformant from dropping and the gene encoding the target protein from dropping off.
  • the selectable marker when the selectable marker is a drug resistance gene, the corresponding drug can be added to the medium, and when the selectable marker is an auxotrophic complementary gene, the corresponding nutrient factor can be removed from the medium. it can.
  • a suitable inducer for example, IPTG or the like
  • the culture conditions of the transformant are not particularly limited as long as the productivity of the target protein and the growth of the host are not hindered, and are usually 10 to 40 ° C., preferably 20 to 37 ° C. and 5 to 100. Do time.
  • the pH can be adjusted using an inorganic or organic acid, an alkaline solution, or the like.
  • Examples of the culture method include solid culture, stationary culture, shaking culture, and aeration and agitation culture.
  • the target protein When the target protein is produced in the microbial cells or cells after culturing, the target protein can be collected by disrupting the microbial cells or cells.
  • As a method for disrupting cells or cells high-pressure treatment using a French press or homogenizer, ultrasonic treatment, grinding treatment using glass beads, enzyme treatment using lysozyme, cellulase, pectinase, etc., freeze-thawing treatment, hypotonic solution treatment, It is possible to use a lysis inducing treatment with a phage or the like. After crushing, the cells or cell crushing residues (including the cell extract insoluble fraction) can be removed as necessary.
  • Examples of the method for removing the residue include centrifugation and filtration. If necessary, the residue removal efficiency can be increased by using a flocculant or a filter aid.
  • the supernatant obtained after removing the residue is a cell extract soluble fraction and can be a crudely purified protein solution.
  • the target protein is produced in the microbial cells or cells
  • the microbial cells and the cells themselves can be recovered by centrifugation, membrane separation, etc., and used without being crushed.
  • the target protein is produced outside the cells or cells, the culture solution is used as it is, or the cells or cells are removed by centrifugation or filtration.
  • the target protein is collected from the culture by extraction with ammonium sulfate precipitation, and further, if necessary, using dialysis and various chromatography (gel filtration, ion exchange chromatography, affinity chromatography, etc.) It can also be isolated and purified.
  • the production yield of the protein obtained by culturing the transformant is, for example, SDS-PAGE (polyacrylamide gel) in units such as per culture solution, per microbial wet weight or dry weight, or per crude enzyme solution protein. For example, electrophoresis).
  • the target protein can also be produced using a cell-free protein synthesis system that does not use any living cells.
  • the cell-free protein synthesis system is a system that synthesizes a target protein in an artificial container such as a test tube using a cell extract.
  • Cell-free protein synthesis systems that can be used also include cell-free transcription systems that synthesize RNA using DNA as a template.
  • the cell extract to be used is preferably derived from the aforementioned host cell.
  • the cell extract include extracts derived from eukaryotic cells or prokaryotic cells, more specifically, CHO cells, rabbit reticulocytes, mouse L-cells, HeLa cells, wheat germ, budding yeast, E. coli, and the like. Liquid can be used. These cell extracts may be used after being concentrated or diluted, or may be used as they are, and are not limited.
  • the cell extract can be obtained by, for example, ultrafiltration, dialysis, polyethylene glycol (PEG) precipitation or the like.
  • Such cell-free protein synthesis can also be performed using a commercially available kit.
  • reagent kit PROTEIOS TM Toyobo
  • TNT TM System Promega
  • PG-Mate of synthesizer TM Toyobo
  • RTS Roche Diagnostics
  • the target protein produced by cell-free protein synthesis can be purified by appropriately selecting means such as chromatography as described above.
  • the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these examples.
  • MTG variant DNA encoding MTG variant (specifically, MTG precursor variant) consisting of each amino acid sequence shown below is inserted between NdeI-XhoI of pET22b + to construct a recombinant expression plasmid vector did.
  • the underlined amino acids are substitution-mutated amino acids.
  • Amino acid sequence of MTG variant (Y12A) Amino acid sequence of MTG variant (Y12Q) Amino acid sequence of MTG variant (Y16A) Amino acid sequence of MTG variant (Y16Q) Amino acid sequence of MTG variant (K10R / Y12A)
  • the obtained recombinant expression plasmid vector was transformed into E.
  • coli BL21 (DE3) strain using a heat shock method inoculated into an LB agar medium containing ampicillin sodium at 100 ⁇ g / mL, and allowed to stand at 37 ° C. overnight. A colony was obtained.
  • the obtained Escherichia coli colonies were inoculated into 10 mL of LB medium (containing 100 ⁇ g / mL of ampicillin sodium) and cultured at 37 ° C. and 200 rpm for 4 hours. Inoculate in 500 mL of LB medium, and culture at 37 ° C. and 120 rpm.
  • Isopropyl ⁇ -D-1-thiogalactopylanoside is added at a final concentration of 0.5 mM, and the culture temperature is increased. The temperature was lowered to 15 ° C. and the culture was continued for another 16 hours. The cells were collected by centrifugation at 6000 g for 7 minutes. After washing 3 times with 1 ⁇ TBS Buffer (25 mM Tris-HCl, 150 mM NaCl, pH 7.4), all the supernatant was discarded and the pelleted cells were stored frozen at ⁇ 80 ° C.
  • the cryopreserved pellet is dissolved in 15 mL of 1 ⁇ TBS buffer, the cells are disrupted by sonication (Output 4, Duty 20, 12.5 min), and centrifuged (4 ° C., 18,000 ⁇ g, 20 min). The bacterial cells and the protein-containing solution were separated. The obtained solution was filtered through 0.45 ⁇ m and 0.22 ⁇ m PVDF membrane filters to remove insoluble fractions and bacterial cells. The resulting solution was purified with a hexahistidine tag (His Tag) introduced into the C-terminus of Y16A MTG using a HisTrap Excel column (1 mL).
  • His Tag hexahistidine tag
  • a blank 0.2 M Tris-HCl buffer (pH 7.4), a calibration curve dilution series, and 20 ⁇ L of each MTG dilution series were added to a 96-well plate. 3. 80 ⁇ L of substrate solution was added to each well and incubated at 37 ° C. for 10 min. 4). 100 ⁇ L of the reaction stop solution was added, and the absorption at 525 nm was immediately measured with a plate reader. 5. From the calibration curve, the amount of hydroxamic acid produced under each MTG condition was measured, and the specific activity (U / mg) was calculated. Here, the amount of enzyme that generates 1 ⁇ mol of hydroxamate per minute was defined as the TGase activity unit, 1 U (unit).
  • the enzyme activity measurement results under the conditions of pH 6.0 (FIG. 1) and pH 74 (FIG. 2) are shown below. From these results, Y12A MTG and Y12Q MTG showed no activity at pH 6.0, but Y12A MTG showed a little activity at pH 7.4. A slight improvement in activity was also observed for Y12Q MTG.
  • the enzyme activity in the hydroxamate method is remarkably low. From this result, it is considered that the Y12A MTG precursor and the Y12Q MTG precursor do not recognize either or both of Z-QG and hydroxylamine as a substrate, and the access between the MTG and the substrate is greatly reduced. It was strongly suggested.
  • FIG. 3 shows an experimental schematic diagram for evaluating the activity of the MTG mutant by FRET.
  • FIGS. 4 to 11 show the analysis results by FRET and the change over time in the degree of progress of the crosslinking reaction of MTG based on the ratio of the maximum fluorescence intensity of EGFP and the maximum fluorescence intensity of Texas Red (I 610 / I 508 ).
  • NK-tag EGFP recombinant MKHKGSGGGSGGGS (SEQ ID NO: 9) sequence at the N-terminus
  • fluorescent dye FITC- ⁇ -Ala-QG and Y16A MTG variant were mixed in PBS (pH 7.4). And reacted at 37 ° C. for 1 hour.
  • SDS-PAGE was performed to obtain a FITC-derived fluorescent image labeled with the protein using a fluorescent imager (Bio-Rad, Molecular Imager FX Pro).
  • proteins were stained with Coomassie Brilliant Blue (CBB).
  • the concentrations of EGFP to which the substrate peptide tag was added, fluorescent dyes, and various MTGs were set to 1 ⁇ M, 20 ⁇ M, and 1 ⁇ M, respectively.
  • the results are shown in FIGS. From the results of FIGS. 20 and 21, -Between small molecule primary amine substrate and Gln substrate peptide added protein (FIG. 17) Lys substrate peptide-added protein—small molecule Gln substrate (FIG. 18)
  • a fluorescent band was observed in the vicinity of the molecular weight of the EGFP recombinant, it became clear that the cross-linking reaction proceeded between the substrate peptide sequence added to the protein and the small molecule substrate.
  • MTG prosequence variant was also shown to have cross-linking activity.
  • a fluorescent band was confirmed in a portion corresponding to the MTG mutant, although it was not confirmed in the Y12A MTG mutant lane, the mutation was introduced. It was suggested that the primary amine substrate was labeled on the Gln residue.
  • any of the MTG mutant lanes of Y12A, Y12Q, and Y16A in FIG. 21 a fluorescent band was confirmed at a position corresponding to the MTG mutant.
  • DNAs encoding various MTG mutants shown in Table 3 below were prepared, and using the same method as in Example 1, construction of a recombinant expression plasmid vector, Expression and purification were performed to obtain various MTG mutant proteins.
  • DNAs encoding various MTG mutants are No. 5 which are mutation modes shown in the “mutation introduction position” column of Table 3.
  • K-tag EGFP recombinant (MKHKGS (SEQ ID NO: 12) consists of an amino acid sequence having an N-terminus, and MKHKGS-EGFP (SEQ ID NO: 14).
  • Also referred to as a fluorescent dye FITC- ⁇ -Ala-QG and various MTG mutants were mixed in PBS (pH 7.4) and reacted at 37 ° C. for 1 hour.
  • a K-tag EGFP recombinant different from the above consisting of an amino acid sequence having the MRHKGS (SEQ ID NO: 13) sequence at the C-terminus, also referred to as EGFP-MRHKGS (SEQ ID NO: 15)
  • fluorescent dye FITC- ⁇ -Ala-QG and various MTG variants were mixed in PBS (pH 7.4) and reacted at 37 ° C for 1 hour.
  • SDS-PAGE was performed to obtain a FITC-derived fluorescent image labeled with the protein using a fluorescent imager (Bio-Rad, Molecular Imager FX Pro).
  • proteins were stained with Coomassie Brilliant Blue (CBB).
  • the MTG mutant having a mutation introduced into Y12 or Y16 showed a significant improvement in activity. Further, from FIGS. 32 and 33, the MTG mutant having the mutation of K10R / Y12H or K10R / Y12H / Y16H showed pH responsiveness and showed significantly higher activity at pH 6.0 than at pH 7.4. Finally, in FIG. 34, the expression of activity was confirmed for a single mutant having no mutation in Y12 or Y16 and having a mutation of K10D or K10E.
  • an MTG mutant that can be easily produced (purified) in an expression system using a microorganism such as Escherichia coli as a host, that is, an active MTG having transglutaminase activity.
  • a microorganism such as Escherichia coli as a host
  • an active MTG having transglutaminase activity If it is the said MTG variant, the protease process at the time of expression refinement
  • the MTG variant according to the present invention does not show a crosslinking activity with respect to a small molecule substrate having low reactivity, and is a nonspecific crosslinking that may cause a problem when MTG is used for site-specific modification of a protein. It can prevent reaction.
  • the MTG variant according to the present invention recognizes a substrate by the MTG variant having the propeptide only when a peptidic substrate having a higher affinity than the propeptide into which the mutation has been introduced is used.
  • a peptide sequence-selective cross-linking reaction can be performed.
  • the MTG mutant according to the present invention can also be used for site-specific modification of a target protein substrate in a host.
  • Sequence number 3 Recombinant protein Sequence number 4: Recombinant protein Sequence number 5: Recombinant protein Sequence number 6: Recombinant protein Sequence number 7: Recombinant protein Sequence number 8: Peptide Sequence number 9: Peptide Sequence number 10: Peptide Sequence number 11: Peptide Sequence number 12: Peptide Sequence number 13: Peptide Sequence number 14: Recombinant protein Sequence number 15: Recombinant protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une transglutaminase microbienne active (MTG) qui ne nécessite pas de traitement de protéase dans un système d'expression de protéine en utilisant un hôte universel tel qu'Escherichia coli, c'est-à-dire une MTG mutée ayant une activité transglutaminase, et un procédé de production de celle-ci. L'invention est une protéine obtenue par mutation d'un acide aminé dans la séquence d'acides aminés de la fraction propeptide de la transglutaminase microbienne de type sauvage, la protéine étant caractérisée en ce qu'elle a une activité transglutaminase.
PCT/JP2017/024881 2016-07-01 2017-06-30 Protéine recombinée ayant une activité transglutaminase Ceased WO2018004014A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018525324A JPWO2018004014A1 (ja) 2016-07-01 2017-06-30 トランスグルタミナーゼ活性を有する組換えタンパク質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016131883 2016-07-01
JP2016131883 2016-07-01

Publications (1)

Publication Number Publication Date
WO2018004014A1 true WO2018004014A1 (fr) 2018-01-04

Family

ID=60787147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/024881 Ceased WO2018004014A1 (fr) 2016-07-01 2017-06-30 Protéine recombinée ayant une activité transglutaminase

Country Status (2)

Country Link
JP (1) JPWO2018004014A1 (fr)
WO (1) WO2018004014A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019181235A1 (fr) * 2018-03-19 2019-09-26 国立大学法人九州大学 Procédé de production d'une protéine lipidée, et protéine lipidée
CN110551675A (zh) * 2018-06-04 2019-12-10 清华大学 谷氨酰胺转氨酶介导的细胞膜表面修饰方法
WO2021178001A1 (fr) * 2020-03-05 2021-09-10 Curie Co. Inc. Procédés pour l'expression de protéines acellulaires de polypeptides matures dérivés de zymogènes et de proprotéines
WO2024232299A1 (fr) * 2023-05-08 2024-11-14 国立大学法人九州大学 Produit de fusion de transglutaminase dérivé de micro-organismes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504170A (ja) * 2005-08-18 2009-02-05 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
WO2009030211A2 (fr) * 2007-09-07 2009-03-12 Martin-Luther-Universität Halle-Wittenberg Transglutaminases stables

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101256A1 (fr) * 2009-03-06 2010-09-10 味の素株式会社 Transglutaminase thermotolérante provenant d'actinomyces

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504170A (ja) * 2005-08-18 2009-02-05 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
WO2009030211A2 (fr) * 2007-09-07 2009-03-12 Martin-Luther-Universität Halle-Wittenberg Transglutaminases stables

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN K. ET AL.: "Enhancement of Streptomyces transglutaminase activity and pro-peptide cleavage efficiency by introducing linker peptide in the C-terminus of the pro-peptide", J. IND. MICROBIOL. BIOTECHNOL., vol. 40, no. 3, 2013, pages 317 - 325, XP035330676, DOI: 10.1007/s10295-012-1221-y *
MATSUZAKI, TAKASHI ET AL.: "Shinki Biseibutsu Yurai Transglutaminase Sosei ni Muketa Kiso Kenkyu", DAI 53 KAI PREPRINTS OF JOINT CHEMICAL CONFERENCE OF KYUSHU BRANCH GAIKOKUJIN KENKYUSHA KORYU KOKUSAI SYMPOSIUM, 2 July 2016 (2016-07-02), pages 17 *
RICKERT M. ET AL.: "Production of soluble and active microbial transglutaminase in Escherichia coli for site-specific antibody drug conjugation", PROTEIN SCI., vol. 25, February 2016 (2016-02-01), pages 442 - 455, XP055276114, DOI: doi:10.1002/pro.2833 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019181235A1 (fr) * 2018-03-19 2019-09-26 国立大学法人九州大学 Procédé de production d'une protéine lipidée, et protéine lipidée
JPWO2019181235A1 (ja) * 2018-03-19 2021-03-11 国立大学法人九州大学 脂質化タンパク質の製造方法、及び脂質化タンパク質
CN110551675A (zh) * 2018-06-04 2019-12-10 清华大学 谷氨酰胺转氨酶介导的细胞膜表面修饰方法
CN110551675B (zh) * 2018-06-04 2021-05-11 清华大学 谷氨酰胺转氨酶介导的细胞膜表面修饰方法
WO2021178001A1 (fr) * 2020-03-05 2021-09-10 Curie Co. Inc. Procédés pour l'expression de protéines acellulaires de polypeptides matures dérivés de zymogènes et de proprotéines
WO2024232299A1 (fr) * 2023-05-08 2024-11-14 国立大学法人九州大学 Produit de fusion de transglutaminase dérivé de micro-organismes

Also Published As

Publication number Publication date
JPWO2018004014A1 (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
JP5419220B2 (ja) エステル結合を含む非天然タンパク質の製造方法
JP2005514025A (ja) タンパク質発現及び精製のための方法及び組成
CN113195521A (zh) Mtu ΔI-CM内含肽变体和其应用
WO2018004014A1 (fr) Protéine recombinée ayant une activité transglutaminase
CN116096872A (zh) 热稳定的末端脱氧核苷酸转移酶
CA2991195C (fr) Nouveaux variants de p450-bm3 ayant une activite amelioree
CN110714020B (zh) 一种高效简便纯化蛋白的方法
US11613757B2 (en) Process for extracellular secretion of Brazzein
US8426572B2 (en) Artificial entropic bristle domain sequences and their use in recombinant protein production
CN115261363B (zh) Apobec3a的rna脱氨酶活性测定方法及rna高活性的apobec3a变体
CN114381471B (zh) 一种辅助蛋白在重组蛋白生产中的应用及融合表达系统
WO2024032020A1 (fr) Protéine staygold monomère améliorée et son utilisation
WO2007061136A1 (fr) Procede pour la production de proteine renfermant un acide amine de type non naturel
US8530217B2 (en) Processing of peptides and proteins
JP2008245604A (ja) 高効率耐熱性ｄｎａリガーゼ
JP4631436B2 (ja) メタロエンドペプチダーゼ
JP2005245457A (ja) 耐熱性ホタルルシフェラーゼ、耐熱性ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ及び耐熱性ホタルルシフェラーゼの製造法
CN108699545A (zh) β-内酰胺酶变体
JP2020530029A (ja) ノルボルネン部分を担う新規アミノ酸
CN112055751B (zh) 修饰型酯酶和其用途
JP2009148205A (ja) 高反応性耐熱性ｄｎａリガーゼ
CN121427858A (zh) L-氨基酸脱氨酶突变体及应用
CN117964708A (zh) 一种内含肽及其突变体的应用
JP2002199888A (ja) 好熱性プロリルエンドペプチダーゼ
JPH03285684A (ja) メチオニンアミノペプチダーゼのｄｎａ配列

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018525324

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17820368

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17820368

Country of ref document: EP

Kind code of ref document: A1